Wednesday, February 26, 2025 | 12:36 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Ajanta Pharma Q4 PAT falls 5% to Rs 151 cr; revenue rises to Rs 870 cr

Ajanta Pharma on Tuesday said its consolidated profit after tax declined by 5 per cent to Rs 151 crore for the fourth quarter ended March 2022.

Ajanta Pharma Q4 PAT falls 5% to Rs 151 cr; revenue rises to Rs 870 cr

For the year ended March 31, 2022, the company posted a PAT of Rs 713 crore. It was Rs 654 crore in FY21. Revenue from operations rose to Rs 3,341 crore last fiscal as against Rs 2,890 crore in 2020-21.

Press Trust of India New Delhi

Ajanta Pharma on Tuesday said its consolidated profit after tax declined by 5 per cent to Rs 151 crore for the fourth quarter ended March 2022.

The drug firm had reported a consolidated PAT (Profit After Tax) of Rs 159 crore in the January-March quarter of 2020-21 fiscal.

Revenue from operations rose to Rs 870 crore during the period under review from Rs 757 crore in the year-ago period, the Mumbai-based drug firm said in a regulatory statement.

For the year ended March 31, 2022, the company posted a PAT of Rs 713 crore. It was Rs 654 crore in FY21. Revenue from operations rose to Rs 3,341 crore last fiscal as against Rs 2,890 crore in 2020-21.

 

The company said its board has approved the issuance of bonus equity shares in the proportion of 1 share of Rs 2 each for every 2 shares of Rs 2 each.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 10 2022 | 7:26 PM IST

Explore News